Pittsburgh, Pennsylvania, United States
Michael Hufford, Paulo A Fontes, Eric Lagasse
2017
Private company
Series A
18
Longevity Vision Fund, Juvenescence
Cell Loss
End-stage liver disease, immunosenescence
cell therapy, ectopic organ regeneration
Phase 2 Trials
LYG-LIV0001
LyGenesis, Inc. is a cell therapy company focused on organ regeneration, transforming a patient's lymph nodes into bioreactors capable of growing functioning ectopic organs. Our lead clinical indication is for patients with end stage liver disease (ESLD) and our Phase 2a clinical trial will begin in 2021. Other cell therapies in our drug development pipeline focus on regenerating pancreas, kidney, and thymus tissues.